Vanguard Total Intl Stock Index

Alibaba holds Cloud Summit in Hangzhou, may release a major new AI model

Tencent Holdings released the Next Day Disclosure Report on share repurchase

J.P. Morgan maintains 'Buy' rating on Alibaba with a price target of $205

Goldman Sachs reiterates 'Buy' rating on Tencent, encouraged by progress in its AI strategy

Tencent, CATL, and others join a new climate coalition to boost carbon credit demand

Alibaba's Qwen Large Model to Receive a Major Upgrade

HSBC Opens Fifth Wealth Centre Aiming to Become Asia's Largest Wealth Manager

Profund Advisors LLC Reduces Stake in Alibaba

Alibaba Releases Qwen2.5 AI Model Preview, Surpassing GPT-4 in Some Benchmarks

HSBC Opens 4th Wealth & Health Center, Expands Mainland Medical Partnerships for High-Net-Worth Clients

Tencent Open Sources AgentDB to Solve AI Agent Memory Issues, Long-term Memory Accuracy Significantly Improved

SPDB Reiterates 'Buy' Rating on Alibaba (9988.HK)

HSBC prices 1.4 billion AUD senior unsecured kangaroo bonds

HSBC Holdings Raises AUD 1.4 Billion via Three-Part Kangaroo Bond Deal

Goldman Sachs Reaffirms Buy Rating on Tencent with HKD 700 Target Price

Tencent WeChat AI Team Wins ICASSP Best Industrial Paper Award, First for Chinese Enterprise

Alibaba Releases Qwen3.7 Max/Plus Previews, Ranked No.1 in China on Arena

HSBC Opens 5th Premier Wealth Centre in Hong Kong, Appointments Fully Booked

Omdia Report: Alibaba Cloud's Share in China's AI Cloud Market Rises to 38.1%, Staying No.1 in 2025

China Mobile partners with Tencent to launch an AI-native workspace platform

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

HSBC

HSBA

00005

HSBH

HSBC economists predict that central banks will continue to raise policy rates even if a US-Iran peace agreement is reached. They highlight ongoing risks of supply shocks affecting global inflation and growth. Central banks in Australia and Norway are already under inflationary pressure, with potential rate hikes from the European Central Bank and Bank of England in mid-year. HSBC also expects further rate increases in the Philippines, India, and Indonesia later this year.

CoinLive

HSBC Holdings Plc

HSBC HOLDINGS

HSBC Holdings plc ADRhedged

HSBC 5xShortSG241213

HSBC Economists Predict Continued Rate Hikes Despite Potential US-Iran Peace

HSHD

HSBC has launched a $4 billion credit facility in mainland China to support the global expansion of clean energy and low-carbon industries. The facility aims to help businesses scale internationally, particularly in ASEAN, and facilitate decarbonization efforts. It will provide financing across various sectors, including clean power and electrification of transport, while enhancing Singapore's role as a key investment hub. HSBC emphasizes the importance of accessible clean-energy supply chains for transitioning to renewables and aims to assist Chinese businesses in bringing clean technologies to market efficiently.

- HSBC has launched a $4 billion Sustainability and Transition Credit Facility in mainland China to support clean energy and low-carbon businesses looking to expand internationally, particularly in ASEAN.  
- The initiative aims to foster decarbonization and is expected to enhance Singapore’s role as a key investment hub, facilitating access to renewable energy infrastructure for ASEAN nations.  
- With a growing demand for clean technologies, HSBC’s efforts include tailored financial solutions and collaborations to aid businesses in their transition to sustainable practices and technologies.

TechNode

HSBC HK SDR 5to1

HSBC launches $4B credit facility supporting global expansion of China’s low carbon industries

HSBC has launched a $4 billion credit facility to support mainland Chinese clean energy firms in their international expansion, particularly in the ASEAN region. The Sustainability and Transition Credit Facility will finance various sectors, including clean power and AI. Singapore is expected to play a key role in deploying these funds, with strong interest from Chinese companies to expand into ASEAN through the city-state, according to HSBC's Gilbert Ng.

- HSBC has launched a $4 billion credit facility aimed at helping mainland Chinese companies in clean energy and low-carbon sectors scale internationally, particularly in the ASEAN region.  
- The Sustainability and Transition Credit Facility will finance businesses in various sectors, including clean power and electrification of transport, with Singapore expected to play a key role in deploying these funds.  
- HSBC highlights strong interest from Chinese clean energy firms to enter ASEAN through Singapore, enhancing sustainable finance options and supporting the region's capital mobilization for climate action.

Singapore Business Review

HSBC deploys $4b for Chinese clean energy firms seeking overseas expansion

REGN

The FDA has granted breakthrough therapy designation to baxdrostat for uncontrolled hypertension, a significant milestone for patients. Meanwhile, the agency faces instability with leadership departures, raising concerns about regulatory consistency. Additionally, Regeneron has entered a multibillion-dollar collaboration with Parabilis Medicines to develop new therapeutic candidates using AI-driven drug discovery.

Pharmexec

Regeneron Pharma

AstraZeneca

VG Health

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

VanEck Biotech ETF

iShares Global Healthcare

iShares US Pharma

Health Care Select Sector SPDR

iShares Biotechnology ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>

AstraZeneca received FDA approvals for Baxfendy, a hypertension treatment, and Enhertu for early HER2-positive breast cancer. Baxfendy targets uncontrolled hypertension, while Enhertu's approvals cover neoadjuvant and adjuvant settings. These milestones will result in $155 million payments to Daiichi Sankyo. AstraZeneca shares rose 1.56% to $184.42, despite a 9.1% decline over the past month.

Fidelity

AstraZeneca PLC

Mineralys Therapeutics

Daiichi Sankyo Company, Limited

Daiichi Sankyo

S&P 500

AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios

The FDA has approved Baxfendy (baxdrostat) for adults with hypertension inadequately controlled on other medications, marking the first aldosterone synthase inhibitor for this condition. The approval is based on the phase 3 BaxHTN trial, showing significant reductions in systolic blood pressure. This innovative treatment targets a root cause of uncontrolled hypertension, potentially transforming clinical practice. AstraZeneca's acquisition of Baxfendy ties it to a broader cardiorenal strategy, with future success dependent on market positioning and long-term outcomes.

<![CDATA[FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry]]>

DSNKY

4568

The FDA has expanded the use of Enhertu (trastuzumab deruxtecan) for HER2-positive Stage II and III breast cancer, approving it for neoadjuvant and adjuvant settings. The neoadjuvant approval is based on the DESTINY-Breast11 trial, showing a 67.3% pathologic complete response. The adjuvant approval, based on DESTINY-Breast05, demonstrated a 53% reduction in recurrence risk. These approvals enhance treatment options and have significant financial implications, including $155 million in milestone payments.

<![CDATA[FDA Expands Enhertu in Early HER2-Positive Breast Cancer]]>

AstraZeneca has received U.S. approval for its hypertension drug, Baxfendy (formerly baxdrostat), which targets aldosterone to lower blood pressure. The company anticipates peak annual sales exceeding $5 billion. This approval enhances AstraZeneca's portfolio in cardiovascular and renal treatments, following the patent expiration of its diabetes drug, Farxiga. The FDA's decision was based on successful late-stage trials showing efficacy in patients with uncontrolled hypertension. AstraZeneca aims to launch 20 new medicines by 2030, targeting $80 billion in revenue.

MorningStar

CINCOR PHARMA INC

AstraZeneca Gets U.S. Approval for Hypertension Drug

HSBC HOLDINGS has launched a USD4 billion credit facility aimed at supporting mainland enterprises in sustainable development and transition technologies for global expansion. This includes sectors like clean power, data centers, electric vehicles, and AI. The facility will offer extended credit tenors, streamlined approval processes, and customized solutions for eligible enterprises.

- HSBC Holdings has launched a dedicated USD 4 billion credit facility to support mainland enterprises in sustainable development and transition technologies.  
- The facility aims to aid companies in sectors such as clean power, data centers, electric vehicles, and artificial intelligence, with credit tenors extended and approval processes streamlined.  
- Research indicates that global electric vehicle sales may exceed 26 million units this year, while electricity consumption by data centers could nearly double by 2030.

AASTOCKS News

HSBC HOLDINGS  Launches USD4B Credit Facility to Support Global Expansion of Mainland Sustainable Development Enterprises

HSBC has opened its fifth Premier Elite Wealth Centre in Hong Kong, enhancing its service capabilities in response to rising client demand. The centre, located on the 58th floor of Two International Finance Centre, features 34 meeting rooms and a health management hub. HSBC reported double-digit year-on-year growth in its Premier Elite client base in 2025, emphasizing a 'Health + Wealth' strategy to support clients' wealth journeys.

- HSBC has opened its fifth Premier Elite Wealth Centre in Hong Kong, enhancing its service capabilities in response to growing client demand.  
- The new centre, located on the 58th floor of Two International Finance Centre, spans nearly 13,000 square feet and offers 34 meeting rooms alongside a health management hub.  
- HSBC's "Health + Wealth" strategy, supported by strong economic growth and a focus on holistic well-being, aims to accelerate client services and facilitate high-value policy underwriting.

HSBC Opens IFC Wealth Centre; Premier Elite Client Base Logs Double-digit YoY Growth Last Yr

Vanguard Total Intl Stock Index(VXUS.US)

HSBC Economists Predict Continued Rate Hikes Despite Potential US-Iran Peace

HSBC launches $4B credit facility supporting global expansion of China’s low carbon industries

HSBC deploys $4b for Chinese clean energy firms seeking overseas expansion

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>

AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios